doi: 10.3389/fnut.2024.1398059 Received 08 March 2024 Accepted 12 April 2024 Published 29 April 2024 Volume 11 - 2024 Edited by Jorge Carriel Mancilla, Catholic University of Santiago de Guayaquil, Ecuador Reviewed by Ludwig Roberto lvarez Crdova, Catholic University of Santiago de Guayaquil, Ecuador Janeth Castano Jimenez, Indiana University Bloomington, United States Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2024 Tamayo-Trujillo, Ruiz-Pozo, Cadena-Ullauri, Guevara-Ramrez, Paz-Cruz, Zambrano-Villacres, Simancas-Racines and Zambrano
Alexis Pedrick: Smith, Klein, and French wanted in on the craze
Injection site reactions are relatively common, affecting anywhere from 0.5% to 40% of users
Tirzepatide targets GLP-1 and GIP receptors, while semaglutide targets only GLP-1 receptors
Its not covered by insurance, but it can be pretty affordable
Combined with your provider's clinical judgment, this context can guide dosing intensity and formulation selection from PlexusDx's compounded options, including the Microdose GLP-1 Protocol for sensitive individuals
